Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells $169,204.23 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Tuesday, February 18th, Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $252.49 on Friday. The company has a market cap of $32.69 billion, a P/E ratio of -116.36 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm’s fifty day moving average is $254.04 and its two-hundred day moving average is $263.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.94 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on ALNY shares. Piper Sandler restated an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 11th. Barclays lifted their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Finally, Wolfe Research cut Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $299.48.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of ALNY. Huntington National Bank grew its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management bought a new position in Alnylam Pharmaceuticals during the third quarter valued at $29,000. Larson Financial Group LLC grew its stake in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares in the last quarter. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. Finally, Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.